The COVID-19 pandemic has had a significant and lasting impact on the world. Four years
on, despite the existence of effective vaccines, the continuous emergence of new SARS …

Objectives This study aimed to evaluate the effect of administering nirmatrelvir/ritonavir and
molnupiravir before hospitalisation on subsequent critical illness among patients with …

Importance Multiple therapies are available for outpatient treatment of COVID-19 that are
highly effective at preventing hospitalization and mortality. Although racial and …

During the COVID-19 pandemic, elderly patients with underlying condition, such as tumors,
had poor prognoses after progressing to severe pneumonia and often had poor response to …

Aims To identify and synthesize evidence regarding how coronavirus disease 2019 (COVID-
19) interventions, including vaccines and outpatient treatments, have impacted healthcare …

Objectives Although guidelines recommend antiviral therapy for outpatients with COVID-19
who are at high risk of progressing to severe conditions, such as older adults, many patients …

Objectives This study investigated the outcomes of underweight patients with COVID-19 and
the effectiveness of antiviral agents in this population. Methods A retrospective cohort study …

BACKGROUND: Nirmatrelvir/ritonavir (NMV/r) is indicated for the treatment of mild-to-
moderate COVID-19 in adults who are at high risk for progression to severe COVID-19 …

Introduction Molnupiravir (MOV) is an oral antiviral for the treatment of individuals with mild-
to-moderate COVID-19 and at high risk of progression to severe disease. Our objective was …

Meaningful metrics of antiviral activity are essential for determining the efficacy of
therapeutics in human clinical trials. Molnupiravir (MOV) is a broadly acting antiviral …